Abstracts tagged "Takayasu arteritis"

Abstract Number: 013 • 2020 Pediatric Rheumatology Symposium
A Preliminary Data-driven Anatomic Classification for Childhood Takayasu Arteritis (cTA)
Ellen Go¹, Simon Eng ², David Cabral ³ and Rae Yeung ¹, ¹The Hospital for Sick Children, Toronto, Canada, ²Toronto, Canada, ³BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
Background/Purpose: The pattern of arterial involvement and disease severity varies in those affected with cTA. Distinct imaging patterns that have some congruence with clinical phenotype…
Abstract Number: 062 • 2020 Pediatric Rheumatology Symposium
Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study
Gleice Russo¹, Rosa Pereira ², Nadia Aikawa ³, Clovis Silva ⁴, Lucia Campos ⁵, Ana Paula Sakamoto ⁶, Alexandre Souza ⁷ and Maria Teresa Terreri ⁴, ¹Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²University of São Paulo, Sao Paulo, Brazil, ³University of Sao Paulo, Sao Paulo, Brazil, ⁴Sao Paulo, Brazil, ⁵children's institute, Sao Paulo, Brazil, ⁶São Paulo, Brazil, ⁷UNIFESP-EPM, São Paulo, Brazil
Background/Purpose: The improving therapeutic approach towards childhood-onset Takayasu’s arteritis (c-TA) has decreased the mortality rate over the years and increased concerns on how to improve…
Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Uptej Khalsa¹ and Imelda Balboni ¹, ¹Stanford University, Palo Alto, California
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
Abstract Number: 748 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center
Paola Toniati¹, Francesca Regola ¹, Franco Franceschini ¹, Giovanni Bosio ² and Angela Tincani ³, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: A lot of clinical case descriptions about spondyloarthropathy in TAK patients were reported. Recently, a paper about an increased incidence of spondyloarthropathy in TAK…
Abstract Number: 752 • 2019 ACR/ARP Annual Meeting
Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Corrado Campochiaro¹, Alessandro Tomelleri ², Silvia Sartorelli ³, Giulio Cavalli ², De Luca Giacomo ⁴, Elena Baldissera ² and Lorenzo Dagna ², ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, ³Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁴Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy
Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
Abstract Number: 753 • 2019 ACR/ARP Annual Meeting
Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis
Kaitlin Quinn¹, K Bates Gribbons ², Elaine Novakovich ³ and Peter C. Grayson ⁴, ¹Georgetown University Hospital/National Institutes of Health, Washington, DC, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: The natural history of Takayasu’s arteritis (TAK) remains poorly characterized. A “triphasic” pattern of disease has been proposed where constitutional symptoms precede vascular inflammation…
Abstract Number: 757 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis
Hajime Yoshifuji¹, Haruhito Uchida ², Yoshikazu Nakaoka ³, Takahiko Sugihara ⁴, Mitsuaki Isobe ⁵ and Masayoshi Harigai ⁶, ¹Kyoto University, Kyoto, Japan, ²Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Sakakibara Heart Institute, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
Abstract Number: 763 • 2019 ACR/ARP Annual Meeting
Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis
Xiaomeng Cui¹, Xiaomin Dai ¹, Xiufang Kong ², Rongyi Chen ¹, Lili Ma ¹, Ying Sun ³ and Lindi Jiang ¹, ¹Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ²University of Michigan & Fudan University, Ann Arbor, MI, ³Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China, Shanghai
Background/Purpose: To evaluate the efficacy and safety of leflunomide (LEF) for active Chinese Takayasu Arteritis (TA) patients in induction therapy compared with cyclophosphamide (CYC) and…
Abstract Number: 764 • 2019 ACR/ARP Annual Meeting
The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years
Yunjiao Yang¹, Jing Li ², Xinping Tian ¹ and Xiaofeng Zeng ¹, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Medical College, Beijing
Background/Purpose: To investigate the clinical and angiographic features of 591 Chinese Takayasu’s arteritis (TAK) patientsMethods: Clinical and angiographic findings of 591 Chinese TAK patients enrolled…
Abstract Number: 769 • 2019 ACR/ARP Annual Meeting
Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up
Sema Kaymaz-Tahra¹, Fatma Alibaz-Oner ² and Haner Direskeneli ³, ¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ²Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: As a large-vessel vasculitis of young-age group, Takayasu‘s arteritis (TAK) have a high morbidity and mortality caused by the disease or treatments such as…
Abstract Number: 770 • 2019 ACR/ARP Annual Meeting
Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Sema Kaymaz-Tahra¹, Salih Ozguven ², Ali Ugur Unal ³, Fatma Alibaz-Oner ⁴, Tunc Ones ², Tanju Yusuf Erdil ² and Haner Direskeneli ⁵, ¹Marmara University School of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ²Marmara University Faculty of Medicine, Nuclear Medicine, Istanbul, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: FDG-PET-CT is recommended as one of the imaging modalities for the diagnosis and monitoring of primary large-vessel vasculitis (LVV), such as Takayasu’s arteritis (TAK).…
Abstract Number: 1964 • 2019 ACR/ARP Annual Meeting
A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)
Anne Desbois¹, Dragos Ciocan ², David Saadoun ¹, Gabriel Perlemuter ³ and Patrice Cacoub ⁴, ¹GHPS, Paris, France, ²Hôpital Antoine Beclere, Clamart, France, ³Hôpital Clamart, Paris, France, ⁴AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: The pathogenesis of Large Vessel Vasculitis (LVV) is not well understood. There is increasing evidence of a close link between intestinal dysbiosis and systemic…
Abstract Number: 2740 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex
Xiufang Kong ¹ and Amr Sawalha², ¹University of Michigan & Fudan University, Ann Arbor, MI, ²University of Pittsburgh & University of Michigan, Pittsburgh, PA
Background/Purpose: Previous work has revealed a genetic association between Takayasu arteritis and a non-coding genetic variant in an enhancer region within IL6 (rs2069837 A/G). The…
Abstract Number: 2919 • 2019 ACR/ARP Annual Meeting
Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Tomoyuki Mutoh¹, Tsuyoshi Shirai ¹, Tomonori Ishii ², Yuko Shirota ³, Hideo Harigae ¹ and Hiroshi Fujii ¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Hospital, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Background/Purpose: Takayasu arteritis (TAK) is a chronic vasculitis which predominantly affects large vessels. Although anti-endothelial cell antibodies (AECA) had been reported to be involved in…
Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting
Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, David Cuthbertson ⁴, Simon Carette ⁵, Gary S. Hoffman ⁶, Nader A. Khalidi ⁷, Curry L. Koening ⁸, Carol Langford ⁹, Kathleen Maksimowicz-McKinnon ¹⁰, Carol A. McAlear ¹¹, Paul Monach ¹², Larry Moreland ¹³, Christian Pagnoux ¹⁴, Kaitlin Quinn ¹⁵, Joanna Robson ¹⁶, Philip Seo ¹⁷, Antoine Sreih ¹⁸, Ravi Suppiah ¹⁹, Kenneth Warrington ²⁰, Steven Ytterberg ²¹, Raashid Luqmani ³, Richard Watts ²², Peter Merkel ¹⁸ and Peter C. Grayson ²³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Utah Hospital, Salt Lake City, UT, ⁹Cleveland Clinic, Cleveland, OH, ¹⁰Henry Ford Hospital, Wayne State University, Detroit, MI, ¹¹University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University of Pittsburgh, PITTSBURGH, PA, ¹⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁵Georgetown University Hospital/National Institutes of Health, Washington, DC, ¹⁶Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹⁷Johns Hopkins Medicine, Baltimore, MD, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ²⁰Mayo Clinic Rochester, Rochester, MN, ²¹Mayo Clinic College of Medicine, Rochester, MN, ²²Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ²³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].